Innoen Hydrochloride Dopamine Premix 80 mg Injection

Adult administration

Administer as an intravenous injection at a dose of 2–5 µg/min per kg of body weight of dopamine hydrochloride. In severe cases, the dose can be increased to 5–10 µg/min to 20–50 µg/min per kg of body weight for intravenous injection. Adjust according to age and symptoms. If administering more than 50 µg/min per kg of body weight, frequent urine output monitoring is required. Continuously evaluate treatment methods regarding blood volume, increase of myocardial contraction, and distribution of peripheral vascular perfusion.

This medication should be administered at a reduced dose to patients who have previously taken monoamine oxidase inhibitors. Safety and appropriate dosing have not been sufficiently confirmed for pediatric patients, so its use in children is not recommended. This medication loses its effectiveness in alkaline solutions, and should not be mixed with alkaline diluents. It should not be administered to patients with certain diseases, such as pheochromocytoma, uncontrolled tachyarrhythmia, ventricular fibrillation, hyperthyroidism, and closed-angle glaucoma. Patients with a starch allergy should exercise caution when using solutions containing dextrose. Care should be taken in patients with peripheral vascular disease or sulfite allergy, as this medication may induce asthma attacks in some patients. When administering blood, do not use with dextrose-containing solutions, and caution should be taken for fluid overload and electrolyte imbalances during intravenous infusion. This medication can cause a variety of adverse reactions, such as cardiac arrhythmias, changes in blood pressure, gastrointestinal symptoms, skin reactions, headaches, and anxiety, so patients should be closely monitored. Blood pressure, heart rate, urine output, etc. should be carefully monitored, and if any abnormal signs appear, dose adjustments or discontinuation of administration may be necessary. Rapid discontinuation can cause hypotension, so it should be tapered off gradually. This medication may interact with other drugs, so caution is required when used with anesthetics, antidepressants, beta-blockers, and vasoconstrictors. During pregnancy, the risks and benefits for the fetus should be carefully considered before administration, and during breastfeeding, administration should be avoided if possible, or breastfeeding should be discontinued. The elderly should start at a lower dose considering impaired liver, kidney, and heart function. Overdose may cause elevated blood pressure, so administer at a controlled rate or discontinue, and use alpha-blockers if necessary. To prevent tissue damage at the injection site, administer via a large vein and continuously observe the injection site to prevent extravasation. This medication should not be mixed with alkaline solutions, and the color and condition of the solution should be checked before administration; do not use if abnormalities are found. With long-term use, regularly check the fluid and electrolyte balance and acid-base status, and dosage adjustment should be done with caution.

Serious side effects

Dyspnea, asthma attacks; severe edema associated with elevated blood pressure; severe hypertension; tissue necrosis and scab formation due to extravasation; ventricular arrhythmias (at very high doses).

Mild side effects

Ventricular extrasystoles, atrial fibrillation, ventricular tachycardia; peripheral ischemia due to peripheral vasoconstriction; precordial pulse, tachycardia, angina, palpitations, hypotension, hypertension, ventricular arrhythmias, extrasystoles, angina pectoris, vasoconstriction, abnormal conduction, bradycardia, QRS widening, hypernitrogenemia, increased blood pressure; nausea, vomiting, abdominal bloating, abdominal pain, paralytic ileus; piloerection; headache, anxiety, phlebitis, degeneration at the injection site.

This medication should be stored in a sealed container to prevent exposure to air or moisture. It is advisable to maintain storage temperature at general room temperature, which is not particularly cold or hot.

Appearance

Colorless or pale yellow transparent injectable solution contained in a colorless, transparent plastic container.

Package unit

500 milliliters / box